Lead Generation for Vendors Selling to Specialty Pharmacies

Specialty pharmacies - the ones dispensing biologics, oncology drugs, and other high-cost infusion or injectable therapies - run on an entirely different set of pressures than the independent retail pharmacy down the street, but a lot of vendor outreach still treats “pharmacy” as one buyer. A retail pharmacy worries about reimbursement margins on generics and DIR fees. A specialty pharmacy worries about whether it can even get a patient’s prescription filled at all, because access runs through manufacturer-controlled networks and payer approval gates that don’t exist in retail. Vendors selling automation, hub services, or patient-access tools into this space need outreach that reflects that difference, or it reads as generic “pharmacy software” and gets ignored by a buyer who’s already fielding pitches from a dozen point solutions.

Prior authorization turnaround is the whole business

A specialty drug typically can’t be dispensed until a prior authorization clears, and for many therapies that process involves multiple payer touchpoints, missing-documentation cycles, and manual form submission that can stretch approval to weeks. Every day of delay is a patient not getting a needed therapy and a pharmacy holding inventory or losing the fill to a competing specialty pharmacy in the same limited network. A vendor pitch that leads with “we speed up PA turnaround from days to hours” speaks the buyer’s actual P&L. A generic “reduce administrative burden” pitch doesn’t.

Access runs through limited distribution networks, not open market competition

Many specialty drugs are only available through manufacturer-designated limited distribution networks (LDNs), which means a specialty pharmacy’s growth is gated by getting - and keeping - accreditation (URAC, ACHC) and manufacturer relationships, not by winning market share the way a retail pharmacy would. Outreach that understands this dynamic and speaks to accreditation readiness or LDN onboarding lands very differently than outreach that assumes competitive differentiation works the same way it does in retail pharmacy.

The buyer is patient access or pharmacy operations, not “the pharmacist”

The person evaluating a hub-services or prior-auth automation tool is usually a VP of Pharmacy Operations, Director of Patient Access, or similar - someone accountable for fill rate, time-to-therapy, and payer relationships, not a pharmacist filling scripts at the counter. Messaging aimed at “pharmacists” broadly misses the actual decision-maker and reads as unfamiliar with how specialty pharmacy operations are actually structured.

What a working process looks like

1. Lead with time-to-therapy or PA turnaround, framed as the metric this buyer is actually measured on - not generic administrative-burden language.
2. Name the accreditation and LDN context (URAC, ACHC, manufacturer hub relationships) to signal real familiarity with how specialty pharmacy access works.
3. Target patient access and pharmacy operations leadership specifically, not a generic “pharmacy” title list that mixes in retail buyers.
4. Separate specialty pharmacy messaging entirely from retail/independent pharmacy messaging - the same list and sequence for both signals the vendor doesn’t understand the difference.

How Fypion approaches this

For clients selling prior-authorization automation, hub services, or patient-access tools into specialty pharmacy, we build campaigns around time-to-therapy and payer-approval friction - the metrics this buyer actually owns - and we keep specialty pharmacy outreach entirely separate from anything aimed at retail or independent pharmacy, since treating them as one audience is the fastest way to sound like every other “pharmacy software” vendor already in the inbox.

Talk to us if your outbound to specialty pharmacies keeps getting mistaken for a retail-pharmacy pitch.